Background Malignant pleural mesothelioma (MPM) remains a challenging disease to
manage. In the past few decades, extrapleural pneumonectomy (EPP), pemetrexed-based …

Background Malignant pleural mesothelioma (MPM) is an aggressive cancer of the cells
lining the pleural cavity with a low overall incidence. The National Cancer Database (NCDB) …

Background Overall survival (OS) for malignant pleural mesothelioma (MPM) in vulnerable
subgroups remains poorly understood with scarce data available to guide treatment …

7085 Background: Systemic therapy (ST) is the only treatment modality with proven survival
benefit for advanced MPM. Since 2005 MPM patients in Ontario have been eligible for ST …

Background Malignant pleural mesothelioma (MPM) is a rare thoracic malignancy with poor
prognosis and limited treatment options. Immunotherapy shows potential for improved …

Background Malignant pleural mesothelioma (MPM) is a rare and highly aggressive cancer,
most of patients have a poor prognosis. Only a minority patients may benefit from surgical …

Background: Most patients with MPM present with advanced disease and are most often
treated palliatively with platinum-based chemotherapy. Occasional patients are diagnosed …

Introduction Previous prognostic scoring systems for malignant pleural mesothelioma (MPM)
included patients managed surgically and predated the use of pemetrexed. We analyzed …

Opinion statement Malignant pleural mesothelioma (MPM) is a rare neoplasm of the pleural
surfaces that has been associated with asbestos exposure. MPM generally spreads locally …

Background Malignant mesothelioma is a rare but aggressive tumor arising from the pleura,
typically associated with exposure to asbestos. The purpose of this investigation was to …